Equities
Health CarePharmaceuticals & Biotechnology
  • Price (USD)117.92
  • Today's Change1.67 / 1.44%
  • Shares traded3.43m
  • 1 Year change28.71%
  • Beta0.7952
Data delayed at least 15 minutes, as of Nov 15 2019 23:30 GMT.
More ▼

Profile data is unavailable for this security.

About the company

Zoetis Inc. is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals. The Company's segments include the United States and International. Within each of these operating segments, it offers a product portfolio for both livestock and companion animal customers. Its livestock products include Ceftiofur injectable line, Draxxin, Spectramast, Bovi-Shield line, Rispoval line, Suvaxyn/Fostera, Embrex devices and Lutalyse. Its companion animal products include Clavamox/Synulox, Convenia, ProHeart, Revolution/Stronghold, Apoquel, Cerenia and Rimadyl.

  • Revenue in USD (TTM)6.15bn
  • Net income in USD1.47bn
  • Incorporated2012
  • Employees10.00k
  • Location
    Zoetis Inc10 Sylvan WayPARSIPPANY 07054-3825United StatesUSA
  • Phone+1 (973) 822-7000
  • Fax+1 (302) 655-5049
  • Websitehttps://www.zoetis.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
ZTS:NYQ since
announced
Transaction
value
Phoenix Central Laboratory For Veterinarians IncDeal completed31 Oct 201931 Oct 2019Deal completed-7.59%--
Platinum Performance IncDeal completed22 Jul 201922 Jul 2019Deal completed3.36%--
Data delayed at least 15 minutes, as of Nov 15 2019 23:30 GMT.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Iqvia Holdings Inc10.88bn236.00m28.43bn58.00k124.994.6419.522.611.171.2154.0531.600.4794--4.52187,603.501.212.151.442.6634.3732.042.523.61--1.990.64350.007.3215.35-27.97-0.229839.04--
Regeneron Pharmaceuticals Inc7.62bn2.09bn37.23bn7.40k18.943.6016.284.8818.2118.6966.4295.740.6160.74593.131,029,959.0016.8817.7419.3720.7592.2192.9127.4023.683.5125.230.06350.0014.2826.1055.8641.1419.63--
Vertex Pharmaceuticals Incorporated3.62bn583.76m53.95bn2.50k93.4610.2781.9714.902.248.2513.9220.420.59663.398.801,447,865.009.21-5.1111.49-6.6586.6088.1815.43-8.993.32402.490.0992--22.4620.25103.80--13.20--
Zoetis Inc6.15bn1.47bn56.17bn10.00k38.6220.9929.919.133.053.0312.745.620.5661.386.28615,000.0013.5710.6514.9812.7567.7466.0523.9716.423.029.620.706523.639.765.0128.5322.3712.9320.91
Allergan plc15.82bn-9.27bn60.28bn16.90k--1.03--3.81-27.89-27.8547.82178.220.15742.405.42935,952.70-9.21-3.61-10.01-3.8984.9783.23-58.53-28.240.8830.00420.278---0.961743.4124.17---3.81--
Celgene Corporation16.98bn5.80bn78.30bn8.85k13.726.4812.134.618.028.1323.5016.990.44941.307.561,918,437.0015.3510.8817.3512.1296.3195.9434.1624.472.806.520.62080.0017.5218.67-4.8922.5218.86--
Gilead Sciences, Inc.22.37bn2.71bn82.32bn11.00k30.914.0020.063.682.112.0917.4716.270.36235.376.602,033,182.004.3623.085.2028.2279.6084.3712.0443.522.876.070.542517.01-15.2414.59-46.0612.1737.10--
Data as of Nov 15 2019. Currency figures normalised to Zoetis Inc's reporting currency: US Dollar USD

Institutional shareholders

33.71%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 30 Sep 201936.46m7.64%
BlackRock Fund Advisorsas of 30 Sep 201922.50m4.71%
SSgA Funds Management, Inc.as of 30 Sep 201919.60m4.10%
State Farm Investment Management Corp.as of 30 Sep 201919.12m4.01%
AllianceBernstein LPas of 30 Sep 201914.12m2.96%
Fidelity Management & Research Co.as of 30 Sep 201911.67m2.44%
Polen Capital Management LLCas of 30 Sep 201910.53m2.21%
Capital Research & Management Co. (World Investors)as of 30 Sep 201910.36m2.17%
ClearBridge Investments LLCas of 30 Sep 20199.07m1.90%
Massachusetts Financial Services Co.as of 30 Sep 20197.56m1.58%
More ▼
Data from 30 Sep 2019 - 30 Sep 2019Source: FactSet Research Systems Inc.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.